Page 79 - Vitamin D and Cancer

66 A.V. Krishnan and D. Feldman

32. Krishnan AV, Moreno J, Nonn L, Swami S, Peehl DM, Feldman D (2007) Calcitriol as a
chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity.
J Bone Miner Res 22(Suppl 2):V74–V80
33. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D (2004)
Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells
using cDNA microarrays. Prostate 59(3):243–251
34. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, Feldman D (2004) Molecular
activity of 1, 25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells
revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92(3):131–141
35. Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D (2005) Regulation of
prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells.
Cancer Res 65(17):7917–7925
36. Badawi AF (2000) The role of prostaglandin synthesis in prostate cancer. BJU Int 85(4):
451–462
37. Hussain T, Gupta S, Mukhtar H (2003) Cyclooxygenase-2 and prostate carcinogenesis.
Cancer Lett 191(2):125–135
38. Sinicrope FA (2006) Targeting cyclooxygenase-2 for prevention and therapy of colorectal
cancer. Mol Carcinog 45(6):447–454
39. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases
in cancer: progress and perspective. Cancer Lett 215(1):1–20
40. Nonn L, Peng L, Feldman D, Peehl DM (2006) Inhibition of p38 by vitamin D reduces inter-
leukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase
5: implications for prostate cancer prevention by vitamin D. Cancer Res 66(8):4516–4524
41. McCarty MF (2004) Targeting multiple signaling pathways as a strategy for managing pros-
tate cancer: multifocal signal modulation therapy. Integr Cancer Ther 3(4):349–380
42. Maeda S, Omata M (2008) Inflammation and cancer: role of nuclear factor-kappaB activa-
tion. Cancer Sci 99(5):836–842
43. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE
(1998) Cyclooxygenase in biology and disease. Faseb J 12(12):1063–1073
44. Hawk ET, Viner JL, Dannenberg A, DuBois RN (2002) COX-2 in cancer–a player that’s
defining the rules. J Natl Cancer Inst 94(8):545–546
45. Markowitz SD (2007) Aspirin and colon cancer–targeting prevention? N Engl J Med
356(21):2195–2198
46. Garcia Rodriguez LA, Huerta-Alvarez C (2000) Reduced incidence of colorectal adenoma
among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of pub-
lished studies and a new population-based study. Epidemiology 11(4):376–381
47. Nelson JE, Harris RE (2000) Inverse association of prostate cancer and non-steroidal anti-
inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 7(1):169–170
48. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H (2000) Over-expression of
cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42(1):73–78
49. Yoshimura R, Sano H, Masuda C, Kawamura M, Tsubouchi Y, Chargui J, Yoshimura N, Hla
T, Wada S (2000) Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 89(3):
589–596
50. Wagner M, Loos J, Weksler N, Gantner M, Corless CL, Barry JM, Beer TM, Garzotto M
(2005) Resistance of prostate cancer cell lines to COX-2 inhibitor treatment. Biochem
Biophys Res Commun 332(3):800–807
51. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De
Marzo AM, Isaacs WB (2001) Cyclooxygenase-2 is up-regulated in proliferative inflamma-
tory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 61(24):8617–8623
52. Narayanan BA, Narayanan NK, Davis L, Nargi D (2006) RNA interference-mediated
cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation:
modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol
Cancer Ther 5(5):1117–1125